Towards an ecology of collective innovation: Human variome project (HVP), rare disease consortium for autosomal loci (RADical) and data-enabled life sciences alliance (DELSA)

Current Pharmacogenomics and Personalized Medicine

Volumn 9, Issue 4, 2011, Pages 243-251

  Ozdemir, Vural ^a   Rosenblatt, David S ^a,b   Warnich, Louise ^c   Srivastava, Sanjeeva ^d   Tadmouri, Ghazi O ^e   Aziz, Ramy K ^f   Reddy, Panga Jaipal ^d   Manamperi, Aresha ^g   Dove, Edward S ^a   Joly, Yann ^a   Zawati, Ma'n H ^a   Hizel, Candan ^h,i   Yazan, Yasemin ^h   John, Leela ^j   Vaast, Emmanuelle ^k   Ptolemy, Adam S ^l   Faraj, Samer A ^k   Kolker, Eugene ^m,n   Cotton, Richard G H ^o,p  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

^e CENTRE FOR ARAB GENOMIC STUDIES   (United Arab Emirates)

^f CAIRO UNIVERSITY   (Egypt)

^g UNIVERSITY OF KELANIYA   (Sri Lanka)

^h ANADOLU UNIVERSITY   (Turkey)

ⁱ Consultant in Clinical Pharmacy and Global Health Diagnostics ^*  (Turkey)

^j Harvard Medical School ^*  (Canada)

^k MCGILL UNIVERSITY   (Canada)

^l BRIGHAM AND WOMEN S HOSPITAL   (United States)

^m SEATTLE CHILDREN S HOSPITAL   (United States)

ⁿ The Data Enabled Life Sciences Alliance International (DELSA)   (United States)

^o The Human Variome Project International (HVP)   (Australia)

^p UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

Anticipatory ethics; Data enabled life sciences alliance; Delsa; Genomics without borders; Global ethics and international development in pharmacogenomics; Human variome project; Radical; Rare disease consortium for autosomal loci

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; AUTOSOME; BIOMEDICINE; DATA COLLECTION METHOD; DEVELOPING COUNTRY; ECOSYSTEM; EGYPT; FUNDING; GENE LOCUS; GENETIC DATABASE; HEALTH CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; MALARIA; MEDICAL TECHNOLOGY; MUTATION; NON PROFIT ORGANIZATION; PATIENT CARE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPE; PROTEOMICS; RARE DISEASE; SOUTH AFRICA; SRI LANKA; TROPICAL DISEASE; TUBERCULOSIS; TURKEY (REPUBLIC); UNITED ARAB EMIRATES;

EID: 83455186287     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/187569211798377153     Document Type: Article

References (61)

1. Burton H, Nacul L, Sanderson S. Personalised medicine: lessons from birth defects and single gene disorders. Curr Pharmacogenomics Person Med 2011; 9(2): 80-83.
2. Borda-Rodriguez A, Huzair F. Revisiting the Paris Declaration: pharmacogenomics and personalized medicine as accelerators for development aid and effectiveness. Curr Pharmacogenomics Person Med 2011; 9(4): 240-242.
3. OECD. Paris Declaration and Accra Agenda For Action 2005.
4. Khoury MJ. Muin J. Khoury discusses the future of public health genomics and why it matters for personalized medicine and global health. Curr Pharmacogenomics Person Med 2009; 7(3): 158-163. Available from: http://www.benthamscience.com/cppm/openaccessarticles/cppm7-3/003AF.pdf [Accessed October 27, 2010].
5. Warnich L, Drögemöller BI, Pepper MS, et al. Pharmacogenomic research in South Africa: Lessons learned and future opportunities in the rainbow nation. Curr Pharmacogenomics Person Med 2011; 9(3): 191-207. Available from: http://www.benthamdirect.org/ pages/content.php?CPPM/2011/00000009/00000003/007AF.SGM [Accessed October 27, 2010].
6. Reddy PJ, Jain R, Paik YK, et al. Personalized medicine in the age of pharmacoproteomics: A close up on India and need for social science engagement for responsible innovation in post-proteomic biology. Curr Pharmacogenomics Person Med 2011; 9(3): 159-167.
7. Ozdemir V, Muljono DH, Pang T, et al. Asia-Pacific Health 2020 and genomics without borders: co-production of knowledge by science and society partnership for global personalized medicine. Curr Pharmacogenomics Person Med 2011; 9(1): 1-5.
8. Editorial. Two days in New York: reflections on the UN NCD Summit. Lancet Oncol 2011; 12(11): 981.
9. Kickbusch I. Governance for health in the 21st century. Geneva: WHO Regional Office for Europe 2011. Available from: http://www.euro.who.int/__data/assets/pdf_file/0010/148951/RC61 _InfDoc6.pdf. [Accessed October 27, 2011].
10. Wynne B. Lab work goes social, and vice versa: Strategising public engagement processes: commentary on: What Happens in the Lab Does Not Stay in the Lab: Applying Midstream Modulation to Enhance Critical Reflection in the Laboratory. Sci Eng Ethics 2011 Oct 21 [Epub ahead of print].
11. Cotton RG, Vihinen M, den Dunnen JT, et al. Genetic tests need the Human Variome Project. Genet Test Mol Biomarkers 2011; 15(1-2): 3.
12. Patrinos GP, Al Aama J, Al Aqeel A, et al. Recommendations for genetic variation data capture in developing countries to ensure a comprehensive worldwide data collection. Hum Mutat 2011; 32(1): 2-9.
13. Rosenblatt DS. A RaDiCAL approach to gene discovery. J Med Genet 2011; 48(9): 577-8.
14. Ozdemir V. Pharmacogenomics: Reflections on the old and new social, ethical and policy issues in postgenomics medicine. In: Pharmacogenomics in Psychiatry. Schwab M, Kaschka W, Spina E. (Eds.), Basel: S. Karger AB 2010; pp. 12-29.
15. Fisher E, Mahajan RL, Mitcham C. Midstream modulation of technology: Governance from within. Bullet Science Technol Soc 2006; 26: 485-496.
16. Barben D, Fisher E, Selin C, et al. Anticipatory governance of nanotechnology: Foresight, engagement and integration. In: The Handbook of Science and Technology Studies. Hackett EJ, Amsterdamska O, Lynch M, Wajcman J, Eds. Cambridge, MA: MIT Press 2008; pp. 979-1000.
17. Kickbusch I. Healthy Societies: addressing 21st century health challenges. Adelaide: Department of the Premier and Cabinet, State of South Australia 2008.
18. Knoppers BM, Harris JR, Tassé AM, et al. Towards a data sharing Code of Conduct for international genomic research. Genome Med 2011; 3(7): 46.
19. Dove ES, Joly Y, Knoppers BM. Trade-secret model: legal limitations. Science. 2011; 333(6049): 1575.
20. Ozdemir V, Smith C, Bongiovanni K, et al. Policy and dataintensive scientific discovery in the beginning of the 21st century. OMICS 2011; 15(4): 221-225.
21. Hotez PJ. New antipoverty drugs, vaccines, and diagnostics: a research agenda for the US President's Global Health Initiative (GHI). PLoS Negl Trop Dis 2011; 5: e1133.
22. Hey T, Tansley S, Tolle K. The Fourth Paradigm: Data-Intensive Scientific Discovery. Redmond, WA: Microsoft 2009. Available from: http://research.microsoft.com/en-us/collaboration/fourthparadigm/ [Accessed October 27, 2011].
23. Hather GJ, Haynes W, Higdon R, et al. The United States of America and scientific research. PLoS One 2010; 5(8): e12203.
24. Kolker E. A vision for 21st century US Policy to support sustainable advancement of scientific discovery and technological innovation. OMICS 2010; 14(4): 333-335.
25. The Human Variome Project. Available from: www. humanvariomeproject.org [Accessed October 27, 2011].
26. Watkins D, Schwartzentruber JA, Ganesh J, et al. Novel inborn error of folate metabolism: identification by exome capture and sequencing of mutations in the MTHFD1 gene in a single proband. J Med Genet 2011; 48(9): 590-592.
27. Schofield PN, Eppig J, Huala E, et al. Research funding. Sustaining the data and bioresource commons. Science 2010; 330(6004): 592-593.
28. US National Science Foundation (NSF). Task Force Report Washington DC: NSF 2011. Available from: http://www.nsf.gov/od/oci/taskforces/ [Accessed October 27, 2011].
29. Kolker E. The 2nd Data-Intensive Science Workshop Report (DISW2). Transition of bioinformatics to clouds: Opportunities and challenges. Washington DC: National Science Foundation 2011.
30. Abbott A. Rare-disease project has global ambitions. Nature 2011; 472: 17.
31. Editorial. What is the Human Variome Project? Nat Genet 2007; 39: 423.
32. Cotton RGH, Participants of the 2006 Human Variome Project Meeting. Recommendations of the 2006 Human Variome Project meeting. Nat Genet 2007; 39: 433-6.
33. Kohonen-Corish MR, Al-Aama JY, Auerbach AD, et al. How to catch all those mutations--the report of the third Human Variome Project Meeting, UNESCO Paris, May 2010. Hum Mutat 2010; 31(12): 1374-81.
34. Cotton RG, Al Aqeel AI, Al-Mulla F, et al. Capturing all diseasecausing mutations for clinical and research use: toward an effortless system for the Human Variome Project. Genet Med 2009; 11(12): 843-9.
35. Kohonen-Corish MR, Macrae F, Genuardi M, et al. Deciphering the colon cancer genes - report of the InSiGHT-Human Variome Project Workshop, UNESCO, Paris 2010. Hum Mutat 2011; 32(4): 491-4.
36. Kolker E. Special issue on data-intensive science, OMICS 2011; 15(4): 197-8.
37. Abdelhak S, Adebamowo C, Adeyemo A, et al. Harnessing genomic technologies toward improving health in Africa: opportunities and challenges. Available from: http://h3africa.org/ h3africa_whitepaper.pdf [Accessed Oct 27, 2011].
38. Human Variome Project Working Groups. Available from: http://www.humanvariomeproject.org/index.php/activities/workinggroups [Accessed October 27, 2011].
39. Pepper MS. Launch of the Southern African Human Genome Programme. S Afr Med J 2011; 101(5): 287-8.
40. Editorial. Helping Hand. Nature 2011; 474(7353): 542.
41. Bissar-Tadmouri N, Tadmouri GO. Bibliometric analyses of biomedical research outputs in Lebanon and the United Arab Emirates (1988-2007). Saudi Med J 2009; 30(1): 130-9.
42. The Catalogue for Transmission Genetics in Arabs (CTGA) Database 2011. Available from: http://www.cags.org.ae/ctga_search.html [Accessed October 27, 2011].
43. Science-Metrix. 30 Years in Science. Montreal: Science-Metrix 2010. Available from: http://www.science-metrix.com/30years-Paper.pdf [Accessed October 27, 2011].
44. SCImago. SJR - SCImago Journal & Country Rank 2010. Available from: http://www.scimagojr.com [Accessed October 27, 2011].
45. Aziz RK, Kansal R, Abdeltawab NF, et al. Susceptibility to severe streptococcal sepsis: use of a large set of isogenic mouse lines to study genetic and environmental factors. Genes Immun 2007; 8(5): 404-415.
46. King Abdullah University of Science and Technology. Red Sea Expedition 2011. Available from: http://krse.kaust.edu.sa/index.html [Accessed October 27, 2011].
47. Keser I, Sanlioglu AD, Manguoglu E, et al. Molecular analysis of beta-thalassemia and sickle cell anemia in Antalya. Acta Haematol 2004; 111(4): 205-10.
48. Hizel C, Gök S, Sardas S, et al. Personalized and predictive medicine in Turkey: A symposium report of the Istanbul Working Group on Personalized Medicine, Istanbul, Turkey, September 10-12, 2009. Curr Pharmacogenomics Person Med 2009; 7(4): 297-301.
49. Gorakshakar AC, Colah RB. Cascade screening for betathalassemia: A practical approach for identifying and counseling carriers in India. Indian J Community Med 2009; 34(4): 354-6.
50. Hardy BJ, Séguin B, Singer PA, et al. From diversity to delivery: the case of the Indian Genome Variation initiative. Nat Rev Genet 2008; 9(Suppl 1): S9-14.
51. Dissanayake VHW. The Sri Lankan Personal Genome Project (SLPGP). Human Genome Meeting 2011. 4th Pan Arab Human Genetics Conference, Dubai, U.A.E., March 16, 2011.
52. Joly Y. Open biotechnology: licenses needed. Nat Biotechnol 2010; 28(5): 417-9.
53. Joly Y, Livingstone A, Dove ES. Moving beyond commercialization: Strategies to maximize the economic and social impact of genomics research. Genome Canada GE3LS Series Policy Brief (No. 5) 2011 (in press).
54. Public Population Project in Genomics (P3G) 2011. Available from: http://www.p3g.org [Accessed on October 27, 2011].
55. Faraj S, Xiao Y. Coordination in fast-response organizations. Management Science, 2006; 52(8): 1155-69.
56. Majchrzak A, More PHB, Faraj S. Transcending knowledge differences in cross-functional teams. Organization Science 2011; orsc. 1110.0677 v1111.
57. Vaast E, Walsham G. Trans-situated learning: supporting a network of practice with an information infrastructure. Information Systems Research 2009; isre. 1080.0228 v1081.
58. Ostrom E. Collective Action and the Evolution of Social Norms. Journal Econ Perspectives 2000; 14(3): 137-158.
59. Ptolemy AS. Biomarker diversity, validation and clinical translation: Tenets for emergent personalized medicine initiatives. Curr Pharmacogenomics Person Med 2011; 9(4): 286-298.
60. Rohde H, Qin J, Cui Y, et al. Open-source genomic analysis of Shiga-toxin-producing E. coli O104:H4. N Engl J Med 2011; 365(8): 718-724.
61. Aziz RK, Saad R, Rizkallah MR. PharmacoMicrobiomics or how bugs modulate drugs: an educational initiative to explore the effects of human microbiome on drugs. BMC Bioinformatics 2011; 12(Suppl 7): A10.